Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD2014 with or without rituximab in relapsed or refractory diffuse large B-cell lymphoma
ISRCTN10760016Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Jul 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, open-label trial of vistusertib and rituximab in diffuse large B-cell lymphoma (DLBCL) and mature B-cell lymphoma (2 arms), sponsored by University of Birmingham. Primary endpoint: Best overall response rate. Started Jul 2015; status: completed.
02
Drugs
vistusertibrituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)mature B-cell lymphoma
Beyond the preview
Go deeper on ISRCTN10760016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN10760016.